Search

Purpose. To evaluate the regeneration of an infected skin wound in experimental steroid hyperglycemia in rats.Materials and methods. Regeneration of an infected rat skin wound (n = 30) was evaluated on the background of steroid hyperglycemia. Depending on the type of wound surface treatment, all observed animals were divided into 3 groups: the first group (n = 10) was treated with an ointment containing Cymbopogon proximus per os administration; the second group (n = 10) was treated with an ointment containing sodium fusidate 2 %; the third group (n = 10, control) the wound was treated with vaseline. After five days, local changes in the wound area and the activity of its regeneration were evaluated. We also studied the blood changes: the composition of the shaped elements and the content of total protein, albumins, transaminase activity (ALT, AST), total cholesterol, urea and creatinine.Results. The use of Cymbopogon proximus orally by rats of the first group, with induced diabetes mellitus, contributes to a decrease in serum glucose levels by almost two times compared with the second and third groups. Ointment containing Cymbopogon proximus has immunomodulatory properties: it prevents the development of leukopenia, promotes the activation of agranular immunocytes. The use of Cymbopogon proximus extract has a positive effect on the rate of wound regeneration due to several factors: reduction of hyperemia and edema, stimulation of leukocyte activity, and as a consequence activation of regeneration. We did not find a significant difference in the rate of wound regeneration when treated with an ointment based on Cymbopogon proximus extract and an ointment containing sodium fusidate (p > 0.05).Conclusion. The regeneration activity of an infected wound in rats with steroid hyperglycemia does not significantly differ when treated with antimicrobial ointment and Cymbopogon proximus. The extract of Cymbopogon proximus has a double effect in vivo: it reduces glucose levels and promotes wound healing in the condition of hyperglycemia, which is promising in the treatment of complications in diabetes mellitus.

The results of treatment in patients with skin cancer using the method of photodynamic therapy (PDT) with alasens are represented in the article. The study enrolled 25 patients with stage 1 tumor including 23 patients with previously untreated tumors and 2 – with recurrent disease. Superficial tumor was diagnosed in 17 patients and 8 patients had nodal tumor. Alasens was used locally as application of 20% ointment on involved skin area with 6h exposure. The PDT session was performed on a single occasion immediately after the end of exposure (power density of laser irradiation of 50–100 mW/cm2, light dose – 150–200 J/cm2). All patients had fluorescence diagnosis (FD) prior to application of the ointment and before PDT. The results of FD showed that intensity of porphyrin fluorescence in tumor prior to administration of alasens had near no difference from intensity of porphyrin fluorescence in normal skin (12.5±0.7 and 10.0±0.7 r.u., respectively). Six hours after application of the ointment with alasens the fluorescence intensity of protoporphyrin IX increased almost 5-fold (59.7±5.3 r.u.), the fluorescence intensity in normal skin remained near baseline level during the follow-up period (maximally 11.6±1.0 r.u.). Two months after PDT the complete tumor regression was confirmed in 21 patients, partial – in 3 and stabilization of tumor growth in 1 patient. In addition, patients with superficial disease had complete regression in 94.1% of cases and partial regression in 5.9% while for patients with nodal tumor – 62.5% and 25%, respectively, stabilization – in 12.5%.

The results of treatment in patients with skin cancer using the method of photodynamic therapy (PDT) with alasens are represented in the article. The study enrolled 25 patients with stage 1 tumor including 23 patients with previously untreated tumors and 2 – with recurrent disease. Superficial tumor was diagnosed in 17 patients and 8 patients had nodal tumor. Alasens was used locally as application of 20% ointment on involved skin area with 6h exposure. The PDT session was performed on a single occasion immediately after the end of exposure (power density of laser irradiation of 50–100 mW/cm2, light dose – 150–200 J/cm2). All patients had fluorescence diagnosis (FD) prior to application of the ointment and before PDT. The results of FD showed that intensity of porphyrin fluorescence in tumor prior to administration of alasens had near no difference from intensity of porphyrin fluorescence in normal skin (12.5±0.7 and 10.0±0.7 r.u., respectively). Six hours after application of the ointment with alasens the fluorescence intensity of protoporphyrin IX increased almost 5-fold (59.7±5.3 r.u.), the fluorescence intensity in normal skin remained near baseline level during the follow-up period (maximally 11.6±1.0 r.u.). Two months after PDT the complete tumor regression was confirmed in 21 patients, partial – in 3 and stabilization of tumor growth in 1 patient. In addition, patients with superficial disease had complete regression in 94.1% of cases and partial regression in 5.9% while for patients with nodal tumor – 62.5% and 25%, respectively, stabilization – in 12.5%.